Presurgical treatment with letrozole in patients with early-stage breast cancer
Some tumors use estrogen in the body to assist with growth. Letrozole is a drug that is
prevents cells from producing estrogens. This should assist with the slowing of growth of
tumor cells. Letrozole also promotes cell destruction by inhibiting a cellular destruction
The objectives of this study will look at the differences between the cellular destruction
pathway before and after letrozole use, and the differences in the cellular destruction
pathway in participants that have received letrozole versus those who did not. The study
will also look at a gene in all participants called Ki67. This gene is associated with the
rate of tumor cell growth. The study will measure the levels of Ki67 and compare them to
the amount of activation of the cellular destruction pathway.
Participants in this study will have undergone a diagnostic biopsy of their breast tissue.
In order to meet these objectives, one group of participants (Arm A) will not receive
letrozole. Tissue leftover from their diagnostic biopsy will be treated with RAD001
(Everolimus) in the laboratory and the effects of this drug on the cellular destruction
pathway will be studied.
The other group of participants (Arm B) will take letrozole for a minimum of 10 and maximum
of 21 days. They will have a second tumor sample taken as part of their surgical procedure
completed to remove the tumor tissue. Any differences in the cellular destruction pathway
before and after exposure to letrozole will be measured.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.